SAN FRANCISCO, April 11, 2018 /PRNewswire/ --
The global research antibodies market size is expected to
reach USD 4.30 billion
by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 6.1% during the forecast period. The market is predominantly driven by growing number of R&D collaborations
among various public and private organizations to promote technical advancements in product development activities and disease progression studies. Consistent recommendations and guidelines issued by regulatory organizations for laboratories to facilitate generation of accurate results and ensure high-quality standards are slated to enhance adoption of research antibodies over the coming years. For instance, in May 2016
, the International Society for Stem Cell Research issued revised guidelines for cell-based therapies. The revised guidelines were issued with a focus to improve overall efficiency and quality of preclinical studies.
(Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg )
In addition, prominent market players are entering into partnership with R&D entities that are anticipated to open new avenues. In December 2016, Bayer AG and Versant Ventures collaborated to invest around USD 225.0 million for the establishment of a stem cell research facility in Canada to encourage commercialization of regenerative medicine therapies. Increasing prevalence of breast cancer and soaring need for personalized medicine is stirring up the demand for advanced techniques, which in turn is creating ample growth opportunities for the research antibodies market.
Browse full research report with TOC on
"Research Antibodies Market Size, Share & Trends Analysis Report By Product, By Type (Monoclonal, Polyclonal), By Technology, By Source, By Application (Oncology, Neurobiology), By End-use, And Segment Forecasts, 2018 - 2025" at:
Further Key Findings From the Report Suggest:
- Primary antibodies were the most prominent product segment in 2016 owing to greater specificity leading to increased adoption in research activities. The segment is expected to account for more than 65.0% of the overall market revenue by 2025
- On the basis of type, monoclonal antibodies captured substantial share of the market in 2016, owing to high sensitivity for detection of antigens and efficient staining properties with less background noise. The segment is anticipated to rise at a CAGR of 6.6% during the forecast period
- Western blotting commanded the leading share in the market, due to benefits such as better immunogenic response from infectious agents and higher cost efficiency. The immunoprecipitation segment is estimated to post the highest CAGR of just over 7.0% during the same period
- Mouse antibodies are relatively easier to produce and possess greater specificity, thus resulting in higher adoption in R&D and accounting for the largest market share in 2016.
- Oncology accounted for over 36.0% of the overall revenue in 2016 as a consequence of growing cancer population
- Pharmaceutical & biotechnology companies will be the leading end users of research antibodies owing to increased adoption in drug development and discovery. The segment is poised to represent more than 61.0% of the overall revenue by 2025.
- Contract research organizations are likely to be the most promising end-user segment during the forecast period owing to greater cost efficiency
- North America will continue to be the dominant revenue contributor throughout the forecast period owing to local presence of various biotechnology & biopharmaceutical manufacturers striving to compete in the market
- Some of the key players in the global arena are Abcam PLC; Agilent Technologies; and Thermo Fisher Scientific, Inc. The research antibodies market is moderately consolidated and highly competitive due to low entry barriers.
Browse related reports by Grand View Research:
- Clinical Diagnostics Market
- Disease management and increasing demand for lab automation are the key drivers of clinical diagnostics market.
- Aptamers Market - The global aptamers market size was valued at USD 723.6 million in 2016 and is projected to grow at a CAGR of 28.2% during the forecast period.
- Stem Cells Market - The global stem cells market size was estimated at USD 6.87 billion in 2016.
- Molecular Biology Enzymes And Kits & Reagents Market - The global Molecular Biology Enzymes And Kits & Reagentsmarket size was valued at USD 5.77 billion in 2016 and is expected to witness a CAGR of 19.0%
Grand View Research has segmented the global research antibodies market on the basis of product, type, technology, source, application, end-use, and region:
- Research Antibodies Product Outlook (Revenue, USD Million, 2014 - 2025)
- Research Antibodies Type Outlook (Revenue, USD Million, 2014 - 2025)
- Monoclonal Antibodies
- Polyclonal Antibodies
- Research Antibodies Technology Outlook (Revenue, USD Million, 2014 - 2025)
- Western Blotting
- Flow Cytometry
- Research Antibodies Source Outlook (Revenue, USD Million, 2014 - 2025)
- Research Antibodies Application Outlook (Revenue, USD Million, 2014 - 2025)
- Infectious Diseases
- Stem Cells
- Research Antibodies End-use Outlook (Revenue, USD Million, 2014 - 2025)
- Academic & Research Institutes
- Contract Research Organizations
- Pharmaceutical & Biotechnology Companies
- Research Antibodies Regional Outlook (Revenue, USD Million, 2014 - 2025)
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Read Our Blog By Grand View Research:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Corporate Sales Specialist, USA
Grand View Research, Inc
Toll Free: 1-888-202-9519
SOURCE Grand View Research, Inc.